Jaguar Health Inc [JAGX] stock prices are up 5.50% to $1.15 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The JAGX shares have gain 8.49% over the last week, with a monthly amount glided 13.86%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jaguar Health Inc [NASDAQ: JAGX] stock has seen the most recent analyst activity on July 07, 2021, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $5. Previously, Rodman & Renshaw started tracking the stock with Buy rating on July 11, 2017, and set its price target to $2.
The stock price of Jaguar Health Inc [JAGX] has been fluctuating between $0.84 and $21.60 over the past year. Jaguar Health Inc [NASDAQ: JAGX] shares were valued at $1.15 at the most recent close of the market.
Analyzing the JAGX fundamentals
The Jaguar Health Inc [NASDAQ:JAGX] reported sales of 10.48M for trailing twelve months, representing a surge of 10.49%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -2.85%, Pretax Profit Margin comes in at -3.66%, and Net Profit Margin reading is -3.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -2.88 and Total Capital is -0.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1029 points at the first support level, and at 1.0559 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1865, and for the 2nd resistance point, it is at 1.2231.
Ratios To Look Out For
It’s worth pointing out that Jaguar Health Inc [NASDAQ:JAGX]’s Current Ratio is 1.84. Further, the Quick Ratio stands at 1.36, while the Cash Ratio is 0.67. Considering the valuation of this stock, the price to sales ratio is 1.37, the price to book ratio is 0.88.
